This website is written by experts in Pharmaceutical Industry Manufacturing Research and Development and Regulatory Affairs Since 2008 and in 2011 Awarded as one of top 10 websites across world in Pharmaceutical Manufacturing Regulatory
USFDA WHO GMP Guidelines Pharmaceutical Regulations Information about Pharma Quality Managment System Validations Process Validation Cleaning Validation Equipment Qualification Equipment Process Validation Computer System Validation Sterile Product Manufacturing Guidelines Media fill guideline Aseptic Techniques in Sterile dosage form Clean Room Clean Room Classification Guidelines on Area Qualification HVAC AHU HEPA Filter HEPA Filter integrity testing and leak test

Monday, September 1, 2014

Vector vaccine against Ebola under way

Vaccine for Ebola Virus:

Vaccine against Ebola virus is under development, Vaccine Research Center in united states is in the process of developing a vaccine with collaboration of Okairos ( GSK ) this vaccine is an investigational vaccine it is a vector vaccine.Vector is a suitable microorganism, like bacteria or virus (bacteriophages), which is used to deliver genes which after insertion into human body start producing proteins of Ebola virus which in turn act as antigens, human body start identifying and put it into memory in immunity imparting cells, and develop a immune response against this antigen that can protect human body upon actual encounter with Ebola virus.

Hurdles in developing vaccine and drug:
 
There is no drug antigens for treating infection of Ebola virus, if at all all are in investigational stages, neither there is any vaccine, there are many hurdles in developing drug and vaccine. As virus has its own mechanism to protect itself from immune response, antibodies developed against Ebola virus in human body after infection are not able to fight against Ebola virus, they are ineffective.

Systematic analysis of this have resulted in finding that RNA of Ebola virus are protected with a cap like proteins which hinder the approach of antibody to and protect Ebola virus RNA. This protein is known as VP 35. In-depth study of protein VP 35 will give a path to develop a effective drug or a vaccine for treatment of Ebola Virus infection. Researches from The Scripps Research Institute and Iowa State University have studied crystal graphic structure of VP 35 protein bound to Ebola RNA.

No comments:

Pharma Guidelines Most Read

.

Readers Visit Number

This website is Authentic Source of Pharmaceutical Guidelines

This website is Authentic Source of Pharmaceutical Guidelines

Pharma Validations Quality Management System USFDA Guidelines WHO GMP Guidelines New Drug Update





This website consist of detail Information about Pharma Guidelines Pharma Regulatory Affairs USFDA Guidelines WHO Guidelines Pharmaceutical Quality Management System Pharma Validations Process Validation Cleaning Validation Equipment Qualification Equipment Process Validation Computer System Validation Sterile Product Manufacturing Guidelines Media fill guideline Aseptic Techniques in Sterile dosage form Clean Room Clean Room Classification Guidelines on Area Qualification HVAC AHU HEPA Filter HEPA Filter integrity testing and leak test